Bio-Rad Laboratories Inc. Cl A

Bio-Rad Laboratories is a manufacturer and distributor of its own life science research and clinical diagnostics products. The company has two primary segments: Life Science, which is engaged in the life sciences market and develops, manufactures and markets reagents, apparatus and laboratory instruments; and Clinical Diagnostics, which designs, manufactures, sells and supports test systems, informatics systems, test kits and quality controls that serve clinical laboratories in the diagnostics market. The company sells its products and services to a client base comprised of scientific research, healthcare, education and government customers.
  • TickerBIO
  • ISINUS0905722072
  • ExchangeNew York Stock Exchange
  • SectorHealth Care Equipment & Services
  • CountryUnited States

Thanks to a better fundamental star rating, BIO-RAD LABORATORIES sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to BIO-RAD LABORATORIES (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date April 9, 2021, the closing price was USD 602.57 and its expected value was estimated at USD 582.39.

MarketLine Department

Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report

Summary Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Quest Diagnostics Incorporated (Quest or 'the company') provides diagnostic information services. The company offers diagnostic testing service and clinical trials testing service to physicians and patients through its laboratories and its patient service centers. It also prov...

MarketLine Department

The Cooper Companies, Inc. - Strategy, SWOT and Corporate Finance Report

Summary The Cooper Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights The Cooper Companies, Inc. (Cooper or 'the company'), a global medical device company, is engaged in developing, manufacturing and marketing a range of contact lenses. It offers various soft contact lens including toric, multifocal and spherical lenses for several vision defects i...

MarketLine Department

Thermo Fisher Scientific Inc. - Strategy, SWOT and Corporate Finance Report

Summary Thermo Fisher Scientific Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Thermo Fisher Scientific Inc. (Thermo Fisher Scientific or 'the company') is a manufacturer and developer of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery, and diagnostics. Its portfolio of pr...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Market In “Wait-And-See” Phase We started to see waning upside momentum in the S&P 500 last week with the rising wedge breakdown and 2760 support level violation on Tuesday. Despite this, there was no downside follow through the following day as investors digested a new $484B fiscal relief package. This led to the S&P 500 finding support at 2725-2735 which leads us to where we are now -- testing recent highs. We see waning upside momentum and several aspects continue to suggest the S&P 500 remains vulnerable to a pullback, but the market is simply not breaking down. We believe some near-t...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

ullish Tape Despite Inconsistencies Despite the bulls still being in control, we have several ongoing concerns and we cannot rule out the potential for a pullback. Below we highlight developments that are inconsistent with a major bottom in equities that suggests the broad equity market is not yet out of the woods. · S&P 500 Short-Term Levels. We continue to respect the bullish tape, however the S&P 500 remains in the 2855-2900 resistance zone while forming a bearish rising wedge pattern. This pattern results in a breakdown roughly 70% of the time. Still, support at 2760 would need ...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

The Only Thing We Have To Fear Is Fear Itself This powerful quote from FDR can be applied to many facets of life. When it comes to the market, fear can lead investors to buy when it is time to sell, sell when it is time to buy, or freeze up altogether. Step one in conquering this issue starts with preparation and a gameplan. In our report from last Thursday (3/12) titled “Searching For A Bottom” we laid out our gameplan and what we need to see before having confidence that equity markets are bottoming. Below we provide new data points and observations. Yes, equities remain deeply oversold...

MarketLine Department

Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report

Summary Quest Diagnostics Incorporated - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Quest Diagnostics Incorporated (Quest or 'the company') provides diagnostic information services. The company offers diagnostic testing service and clinical trials testing service to physicians and patients through its laboratories and its patient service centers. It also prov...

MarketLine Department

The Cooper Companies, Inc. - Strategy, SWOT and Corporate Finance Report

Summary The Cooper Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights The Cooper Companies, Inc. (Cooper or 'the company'), a global medical device company, is engaged in developing, manufacturing and marketing a range of contact lenses. It offers various soft contact lens including toric, multifocal and spherical lenses for several vision defects i...

MarketLine Department

Thermo Fisher Scientific Inc. - Strategy, SWOT and Corporate Finance Report

Summary Thermo Fisher Scientific Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Highlights Thermo Fisher Scientific Inc. (Thermo Fisher Scientific or 'the company') is a manufacturer and developer of analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery, and diagnostics. Its portfolio of pr...

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

MarketLine Department

Thermo Fisher Scientific Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances And Investments

Summary Marketline's Thermo Fisher Scientific Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Thermo Fisher Scientific Inc since January2007. Marketline's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its comp...

Bio-Rad Laboratories, Inc. - June 2020 (LTM): Peer Snapshot

Peer Snapshot:  Bio-Rad Laboratories, Inc. - June 2020 (LTM) 9 September 2020 (in US millions) FYE Dec-18 FYE Dec-19 LTM Jun-20 FYE Dec-18 FYE Dec-19 LTM Jul-20 FYE Oct-18 FYE Oct-19 LTM Apr-20

Bio-Rad Laboratories, Inc.: Update to credit analysis - Strong financial profile will help weather coronavirus headwind

Bio-Rad will continue to operate with prudent financial policies and low financial leverage over the next 12-18 months despite coronavirus headwinds. But M&A could accelerate.

Bio-Rad Laboratories, Inc. - March 2020 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's announces completion of a periodic review of ratings of Bio-Rad Laboratories, Inc.

Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Bio-Rad Laboratories, Inc.. Global Credit Research- 15 May 2020. New York, May 15, 2020-- Moody's Investors Service has completed a periodic review of the ratings of Bio-Rad Laboratories, Inc. and other ratings that are associated with the same analytical unit.

Bio-Rad Laboratories, Inc. - December 2019 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Thanks to a better fundamental star rating, BIO-RAD LABORATORIES sees an upgrade to Neutral

The independent financial analyst theScreener just awarded an improved star rating to BIO-RAD LABORATORIES (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 2 out of 4 possible stars. With regard to its market behaviour, it remains unchanged and can be qualified as moderately risky. theScreener considers that these elements allow slightly upgrading its rating to Neutral. As of the analysis date April 9, 2021, the closing price was USD 602.57 and its expected value was estimated at USD 582.39.

Ford Equity US Rating and Forecast Report

Ford Equity Research covers more than 4,000 stocks using a proprietary quantitative model that evaluates a company’s earnings strength, its relative valuation and recent price movement. Ford’s five recommendation ratings include strong buy, buy, hold, sell, strong sell. For all stocks in our coverage universe, ratings are generated each week and reflect the fundamental and price data as of the last trading day of the week.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch